Apolipoprotein E genotype does not promote the clinical progression of manifest alzheimer’s disease

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 2, 1996, Pages 120-

  Sarochan, Manfred ^a   Förstl, Hans ^a   Sattel, Herbert ^a   Zerfass, Rainer ^a   Czech, Christian ^b   Beyreuther, Konrad ^b  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; GENE DOSAGE; GENOTYPE; HETEROZYGOTE; HUMAN; LETTER; MALE; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; MALE; PROGNOSIS; TIME FACTORS;

EID: 0030030772     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106865     Document Type: Article

References (8)

1. Corder EH, Saunders AM, Strittmatter WJ, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921-923.
2. Czech C, Mönning U, Tienari P. et al: ApoE-4 allele frequency in clinically diagnosed Alzheimer’s disease, frontal lobe degeneration and non-demented controls. Lancet 1993:342: 1309-1310.
3. Goedert M, Strittmatter W, Roses AD: Risky apolipoprotein in brain. Nature 1994:372:45-46.
4. Roses AD: Apolipoprotein E affects the rate of Alzheimer disease expression. J Neuropathol Exp Neurol 1994;53:429-437.
5. McKhann G, Drachman D, Folstein M. et al: Clinical diagnosis of Alzheimer’s disease. Neurology 1984:34:939-944.
6. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968:114:797-811.
7. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988:24:653-659.
8. Forstl H, Czech C, Sattel H, et al: Apolipoprotein E and Alzheimer's disease. Nervenarzt 1994;65:780-786.